close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

184.31 +0.27 (+0.15%)
Official Closing Price Updated: 4:10 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
18 19 Next >
News headline image
Ten Big Losers To Start The Year. Tesla Isn't The Worst. ↗
Enphase Energy remains out of phase with the stock market. 
Via Investor's Business Daily
News headline image
Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
9 Analysts Have This to Say About Charles River ↗
 
Via Benzinga
News headline image
Expert Ratings for Charles River ↗
 
Via Benzinga
News headline image
8 Analysts Have This to Say About Charles River ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 14, 2024 ↗
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. 
Via Benzinga
News headline image
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Investing in the Aging Population: 3 Healthcare Stocks to Watch ↗
America is becoming a much older country on average. These three healthcare stocks are ideally positioned for this demographic shift. 
Via InvestorPlace
News headline image
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories to Present at Evercore ISI Investor Conference
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
The 3 Most Undervalued Tech Stocks to Buy Now: November 2023 ↗
Growth stocks are rallying but there are still bargains to be found. These three top tech picks can reward long-term investors. 
Via InvestorPlace
News headline image
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook ↗
Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating the  
Via Benzinga
News headline image
Charles River Laboratories Announces Third-Quarter 2023 Results
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Launches Real-Time Research Model Ordering, Introducing an Important Digital Innovation to Research Models & Services Business
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Schedules Third-Quarter 2023 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Provides Access to Relevant, Well-Characterized Pediatric PDX Collection for Oncology Research
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Q4 Stock Predictions: 3 S&P 500 Stocks Ready to Soar ↗
S&P 500 stocks are sliding amid a worrying interest rate environment. However, these three can buck the current downtrend. 
Via InvestorPlace
Topics Stocks
News headline image
Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories International, Inc. (NYSE: CRL) Long Term Investor Alert: Investigation of Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 09/22/2023 -- Certain directors of Charles River Laboratories International, Inc are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
News headline image
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today